“First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).”, J Infect Dis, vol. 207, no. 2, pp. 240-7, 2013.
, “Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.”, J Infect Dis, vol. 211, no. 4, pp. 518-28, 2015.
,